Journal of Cancer Survivorship

, Volume 7, Issue 1, pp 55–62 | Cite as

Cancer research network: using integrated healthcare delivery systems as platforms for cancer survivorship research

  • Larissa Nekhlyudov
  • Sarah M. Greene
  • Jessica Chubak
  • Borsika Rabin
  • Leah Tuzzio
  • Sharon Rolnick
  • Terry S. Field



Much progress has been made in cancer survivorship research, but there are still many unanswered questions that can and need to be addressed by collaborative research consortia.


Since 1999, the National Cancer Institute-funded HMO Cancer Research Network (CRN) has engaged in a wide variety of research focusing on cancer survivorship. With a focus on thematic topics in cancer survivorship, we describe how the CRN has contributed to research in cancer survivorship and the resources it offers for future collaborations.


We identified the following areas of cancer survivorship research: surveillance for and predictors of recurrences, health care delivery and care coordination, health care utilization and costs, psychosocial outcomes, cancer communication and decision making, late effects of cancer and its treatment, use of and adherence to adjuvant therapies, and lifestyle and behavioral interventions following cancer treatment.


With over a decade of experience using cancer data in community-based settings, the CRN investigators and their collaborators are poised to generate evidence in cancer survivorship research.

Implications for Cancer Survivors

Collaborative research within these settings can improve the quality of care for cancer survivors within and beyond integrated health care delivery systems.


Cancer survivorship Integrated health care systems Heath services research 


  1. 1.
    Institute of Medicine and National Research Council of the National Academies. From cancer patient to cancer survivor: lost in transition. Washington: The National Academies Press; 2006.Google Scholar
  2. 2.
    Field TS, Cernieux J, Buist DS, Geiger AM, Lamerato L, Hart G, et al. Retention of enrollees following a cancer diagnosis within health maintenance organizations in the Cancer Research Network. J Natl Cancer Inst. 2004;96:148–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Wagner EH, Greene SM, Hart G, Field TS, Fletcher S, Geiger AM, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr. 2005;35:3–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Geiger AM, Buist DS, Greene SM, Altschuler A, Field T. Survivorship research based in integrated healthcare delivery systems: the Cancer Research Network. Cancer. 2008;112:2617–26.PubMedCrossRefGoogle Scholar
  5. 5.
    The HMO Cancer Research Network: Capacity, Collaboration, and Investigation. http://crncancergov/publications/capacity_collaboration_investigation_2010_aprpdf2011 [accessed 2012 Mar 19].
  6. 6.
    Aiello Bowles EJ, Tuzzio L, Ritzwoller DP, Williams AE, Ross T, Wagner EH, et al. Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: implications for future research. Med Care. 2009;47:1091–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Delate T, Aiello Bowles EJ, Pardee R, Wellman RD, Habel LA, Yood MU, et al. Validity of eight integrated healthcare delivery organizations’ administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev. 2012;21:673–80.PubMedCrossRefGoogle Scholar
  8. 8.
    Ritzwoller DP, Carroll N, Delate T, O’Keeffe-Rossetti M, Fishman PA, Loggers ET, et al. Validation of electronic data on chemotherapy use in HMOs. Med Care. 2012. doi:10.1097/MLR.0b013e31824def85.
  9. 9.
    Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, et al. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Nat Cancer Inst. 2012;104:931–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Hazlehurst B, Sittig DF, Stevens VJ, Smith KS, Hollis JF, Vogt TM, et al. Natural language processing in the electronic medical record: assessing clinician adherence to tobacco treatment guidelines. Am J Prev Med. 2005;29:434–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Hazlehurst B, Frost HF, Sittig DF, Stevens VJ. MediClass: a system for detecting and classifying encounter-based clinical events in any electronic medical record. J Am Med Inform Assoc. 2005;12:517–29.PubMedCrossRefGoogle Scholar
  12. 12.
    Avila CC, Quinn VP, Geiger AM, Kerby TJ, St. Charles M, Clough-Gorr KM. Webinar training: an acceptable, feasible and effective approach for multi-site medical record abstraction: the BOWII experience. BMC Res Notes. 2011;4:430.PubMedCrossRefGoogle Scholar
  13. 13.
    Geiger AM, Greene SM, Pardee RE3, Hart G, Herrinton LJ, Macedo AM, et al. A computerized system to facilitate medical record abstraction in cancer research (United States). Cancer Causes Control. 2003;14:469–76.PubMedCrossRefGoogle Scholar
  14. 14.
    Lash TL, Fox MP, Thwin SS, Geiger AM, Buist DS, Wei F, et al. Using probabilistic corrections to account for abstractor agreement in medical record reviews. Am J Epidemiol. 2007;165:1454–61.PubMedCrossRefGoogle Scholar
  15. 15.
    Specimen collection within the CRN: a critical appraisal. http://crncancergov/publications/crn_specimen_collectionpdf2010 [accessed 2012 Mar 19].
  16. 16.
    Greene SM, Geiger AM, Harris EL, Altschuler A, Nekhlyudov L, Barton MB, et al. Impact of IRB requirements on a multicenter survey of prophylactic mastectomy outcomes. Ann Epidemiol. 2006;16:275–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Greene SM, Hart G, Wagner EH. Measuring and improving performance in multicenter research consortia. J Natl Cancer Inst Monogr. 2005;35:26–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Greene SM, Geiger AM. A review finds that multicenter studies face substantial challenges but strategies exist to achieve Institutional Review Board approval. J Clin Epidemiol. 2006;59(8):784–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Doubeni CA, Field TS, Yood MU, Rolnick SJ, Quesenberry CP, Fouayzi H, et al. Patterns and predictors of mammography utilization among breast cancer survivors. Cancer. 2006;106:2482–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Field TS, Doubeni CA, Fox MP, Buist DS, Wei F, Geiger AM, et al. Under utilization of surveillance mammography among older breast cancer survivors. J Gen Intern Med. 2008;23:158–63.PubMedCrossRefGoogle Scholar
  21. 21.
    Nekhlyudov L, Habel LA, Achacoso NS, Jung I, Haque R, Collins LC, et al. Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery. J Clin Oncol. 2009;27:3211–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Lafata JE, Simpkins J, Schultz L, Chase GA, Johnson CC, Yood MU, et al. Routine surveillance care after cancer treatment with curative intent. Med Care. 2005;43:592–9.CrossRefGoogle Scholar
  23. 23.
    Salz T, Weinberger M, Ayanian JZ, Brewer NT, Earle CC, Elston Lafata J, et al. Variation in use of surveillance colonoscopy among colorectal cancer survivors in the United States. BMC Health Serv Res. 2010;10:256–63.PubMedCrossRefGoogle Scholar
  24. 24.
    Rolnick S, Hensley Alford S, Kucera GP, Fortman K, Ulcickas Yood M, Jankowski M, et al. Racial and age differences in colon examination surveillance following a diagnosis of colorectal cancer. J Natl Cancer Inst Monogr. 2005;35:96–101.PubMedCrossRefGoogle Scholar
  25. 25.
    Salloum RG, Hornbrook MC, Fishman PA, Ritzwoller DP, O’Keeffe-Rossetti M, Elston-Lafata J. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer. 2012;118(22):5644–51.Google Scholar
  26. 26.
    Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Annals Intern Med. 2009;151:203–5.Google Scholar
  27. 27.
    Bosco JL, Lash TL, Prout MN, Buist DS, Geiger AM, Haque R, et al. Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2009;18:2979–83.PubMedCrossRefGoogle Scholar
  28. 28.
    Field TS, Bosco JL, Prout MN, Gold HT, Cutrona S, Pawloski PA, et al. Age, comorbidity, and breast cancer severity: impact on receipt of definitive local therapy and rate of recurrence among older women with early-stage breast cancer. J Am Coll Surg. 2011;213:757–65.PubMedCrossRefGoogle Scholar
  29. 29.
    Haque R, Yood MU, Geiger AM, Kamineni A, Avila CC, Shi J, et al. Long-term safety of radiotherapy and breast cancer laterality in older survivors. Cancer Epidemiol Biomarkers Prev. 2011;20:2120–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21(8):1447–51.PubMedCrossRefGoogle Scholar
  31. 31.
    Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101:1712–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Snyder CF, Frick K, Peairs K, Kantsiper M, Herbert R, Blackford A, et al. Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med. 2009;24:469–74.PubMedCrossRefGoogle Scholar
  33. 33.
    Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26:1073–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Snyder CF, Frick KD, Kantsiper ME, Peairs KS, Herbert RJ, Blackford AL, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol. 2009;27:1054–61.PubMedCrossRefGoogle Scholar
  35. 35.
    Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Carducci MA, et al. Preventive care in prostate cancer patients: following diagnosis and for five-year survivors. J Cancer Surviv. 2011;5:283–91.PubMedCrossRefGoogle Scholar
  36. 36.
    Rowland JH, Mariotto A, Alfano CM, Pollack LA, Weir HK, White A. Cancer survivors—United States, 2007. MMMR. 2011;60:26–272.Google Scholar
  37. 37.
    The Kaiser Family Foundation. State Health Facts. http://www.statehealthfactsorg/comparebarjsp?ind=349&cat=7&sub=85&yr=194&typ=2&sort=a2011 [accessed 2012 Mar 19].
  38. 38.
    A National Coalition for Cancer Survivorship and Institute of Medicine National Cancer Policy Forum Workshop TLAFaTNCI. Implementing Cancer Survivorship Care Planning. Washington, D.C.: The National Academies Press; 2007.Google Scholar
  39. 39.
    Chubak J, Tuzzio L, Hsu C, Alfano CM, Rabin B, Hornbrook MC, et al. Providing care to cancer survivors in integrated healthcare delivery systems: practices, challenges, and research opportunities. J Oncol Pract. 2012;8:184–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Wagner EH, Aiello Bowles EJ, Greene SM, Tuzzio L, Wiese CJ, Kirlin B, et al. The quality of cancer patient experience: perspectives of patients, family members, providers and experts. Qual Saf Health Care. 2010;19:484–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006;24:5117–24.PubMedCrossRefGoogle Scholar
  42. 42.
    McCabe MS, Jacobs L. Survivorship care: models and programs. Semin Oncol Nurs. 2008;24:202–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Harrop JP, Dean JA, Paskett ED. Cancer survivorship research: a review of the literature and summary of current NCI-designated cancer center projects. Cancer Epidemiol Biomarkers Prev. 2011;20:2042–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Stricker CT, Jacobs LA, Risendal B, Jones A, Panzer S, Ganz PA, et al. Survivorship care planning after the institute of medicine recommendations: how are we faring? J Cancer Surviv. 2011;5:358–70.PubMedCrossRefGoogle Scholar
  45. 45.
    Noah-Vanhoucke J, Green LE, Dinh TA, Alperin P, Smith RA. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population. Cancer. 2011;117:3322–31.PubMedCrossRefGoogle Scholar
  46. 46.
    Skolarus TA, Zhang Y, Miller DC, Wei JT, Hollenbeck BK. The economic burden of prostate cancer survivorship care. J Urol. 2010;184:532–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Lux MP, Wöckel A, Benedict A, Buchholz S, Kreif N, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer—a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. Onkologie. 2010;33:155–66.PubMedCrossRefGoogle Scholar
  48. 48.
    Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20:2006–14.PubMedCrossRefGoogle Scholar
  49. 49.
    Committee on Psychosocial Services to Cancer Patients/Families in a Community Setting. Cancer care for the whole patient: meeting psychosocial health needs. Washington: The National Academies Press; 2008.Google Scholar
  50. 50.
    Geiger AM, West CN, Nekhlyudov L, Herrinton LJ, Liu IA, Altschuler A, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24:1350–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Rolnick S, Altschuler A, Nekhlydov L, Elmore JG, Greene SM, Harris EL, et al. What women wish they knew before prophylactic mastectomy. Cancer Nursing. 2007;30:1–7.CrossRefGoogle Scholar
  52. 52.
    Nekhlyudov L, Bower M, Herrinton LJ, Altschuler A, Greene SM, Rolnick S, et al. Women’s decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr. 2005;35:55–60.PubMedCrossRefGoogle Scholar
  53. 53.
    Krouse RS, Herrinton LJ, Grant M, Wendel CS, Green SB, Mohler MJ, et al. Health-related quality of life among long-term rectal cancer survivors with an ostomy: manifestations by sex. J Clin Oncol. 2009;27:4664–70.PubMedCrossRefGoogle Scholar
  54. 54.
    Altschuler A, Ramirez M, Grant M, Wendel C, Hornbrook MC, Herrinton L, et al. The influence of husbands ‘or male partners’ support on women’s psychosocial adjustment to having an ostomy resulting from colorectal cancer. J Wound Ostomy Continence Nurs. 2009;36:299–305.PubMedCrossRefGoogle Scholar
  55. 55.
    Liu L, Herrinton LJ, Hornbrook MC, Wendel CS, Grant M, Krouse RS. Early and late complications among long-term colorectal cancer survivors with ostomy or anastomosis. Dis Colon Rectum. 2010;53:200–12.PubMedCrossRefGoogle Scholar
  56. 56.
    McMullen CK, Wasserman J, Altschuler A, Grant ML, Hornbrook MC, Liljestrand P, et al. Untreated peristomal skin complications among long-term colorectal cancer survivors with ostomies. Clin J Oncol Nurs. 2011;15:644–50.PubMedCrossRefGoogle Scholar
  57. 57.
    Grant M, McMullen CK, Altschuler A, Mohler MJ, Hornbrook MC, Herrinton LJ, et al. Gender differences in quality of life among long-term colorectal cancer survivors with ostomies. Oncol Nurs Forum. 2011;38(5):587–96. Oncol Nurs Forum 2011;38:587–96.PubMedCrossRefGoogle Scholar
  58. 58.
    Mazor KM, Roblin DW, Greene SM, Lemay CA, Firneno CL, Calvi J, et al. Toward patient-centered cancer care: patient perceptions of problematic events, impact, and response. J Clin Oncol 2012. J Clin Oncol 2012;Apr 16 [Epub ahead of print].Google Scholar
  59. 59.
    Mazor KM, Greene SM, Roblin D, Lemay CA, Firneno CL, Calvi J, et al. More than words: patients’ views on apology and disclosure when things go wrong in cancer care. Patient Educ Couns. 2011. doi:10.1016/j.pec.2011.07.010.
  60. 60.
    Gustafson DH, Hawkins R, Boberg E, Pingree S, Serlin RE, et al. Impact of a patient-centered, computer-based health information/support system. Am J Prev Med. 1999;16:1–9.PubMedCrossRefGoogle Scholar
  61. 61.
    McTavish FM, Gustafson DH, Owens BH, Hawkins RP, Pingree S, Wise M, et al. CHESS (Comprehensive Health Enhancement Support System): an interactive computer system for women with breast cancer piloted with an underserved population. J Ambul Care Manage. 1995;18:35–41.PubMedGoogle Scholar
  62. 62.
    Epstein RM, Street RL, Jr. Patient-centered communication in cancer care: Promoting healing and reducing suffering. National Cancer Institute 2007;No. 07-6225.Google Scholar
  63. 63.
    Aiello Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104:1293–305.Google Scholar
  64. 64.
    Oeffinger KC, van Leeuwen FE, Hodgson DC. Methods to assess adverse health-related outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev. 2011;20:2022–34.PubMedCrossRefGoogle Scholar
  65. 65.
    Aiello EJ, Buist DS, Wagner EH, Tuzzio L, Greene SM, Lamerato LE, et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008;107:397–403.PubMedCrossRefGoogle Scholar
  66. 66.
    Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat. 2011;130:681–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–37.PubMedCrossRefGoogle Scholar
  69. 69.
    Kwan ML, Weltzien E, Kushi LH, Castillo A, Slattery ML, Caan BJ. Dietary patterns and breast cancer recurrence and survival among women with early-stage breast cancer. J Clin Oncol. 2009;27:919–26.PubMedCrossRefGoogle Scholar
  70. 70.
    Kwan ML, Abrosone CB, Lee MM, Barlow J, Krathwohl SE, Ergas IJ, et al. The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California. Cancer Causes Control. 2008;10:1065–76.CrossRefGoogle Scholar
  71. 71.
    Bhatia S. Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev. 2011;20:2048–67.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Larissa Nekhlyudov
    • 1
  • Sarah M. Greene
    • 2
  • Jessica Chubak
    • 2
    • 3
  • Borsika Rabin
    • 4
  • Leah Tuzzio
    • 2
  • Sharon Rolnick
    • 5
  • Terry S. Field
    • 6
  1. 1.Department of Population MedicineHarvard Medical School/Harvard Pilgrim Health Care InstituteDepartment of MedicineHarvard Vanguard Medical AssociatesBostonUSA
  2. 2.Group HealthResearch InstituteSeattleUSA
  3. 3.Department of EpidemiologyUniversity of Washington School of Public HealthSeattleUSA
  4. 4.Institute for Health Research, Kaiser Permanente ColoradoCRN Cancer Communication Research CenterDenverUSA
  5. 5.HealthPartners Research FoundationMinneapolisUSA
  6. 6.Meyers Primary Care Institute, Fallon Community Health PlanUniversity of Massachusetts Medical School, and Reliant Medical GroupWorcesterUSA

Personalised recommendations